Literature DB >> 12372048

Pharmacogenomics: the future of drug therapy.

Y J Tsai1, H E Hoyme.   

Abstract

Pharmacogenomics aims to optimize patient management by customizing and synthesizing drugs based on genetic variations in drug response. Polymorphisms affecting metabolism, receptors, and absorption can influence drug sensitivity, toxicity, and dosing. The Human Genome Project, DNA chips, and bioinformatics advance the practice of this field by, respectively, identifying polymorphisms related to drug response, determining an individual's profile of polymorphisms, and integrating data to facilitate clinical decision making. Potential benefits of pharmacogenomics include increasing efficacy and preventing adverse drug reactions, thus improving patient care and decreasing costs. These factors imply that a thorough understanding of the principles and applications of pharmacogenomics will be an indispensable part of the future of drug therapy in clinical medicine.

Entities:  

Mesh:

Year:  2002        PMID: 12372048     DOI: 10.1034/j.1399-0004.2002.620401.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  4 in total

Review 1.  The role of cost-effectiveness analysis in the era of pharmacogenomics.

Authors:  Christopher R Flowers; David Veenstra
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  Does pharmacogenomics provide an ethical challenge to the utilisation of cost-effectiveness analysis by public health systems?

Authors:  Adam La Caze
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Current awareness on comparative and functional genomics.

Authors: 
Journal:  Comp Funct Genomics       Date:  2003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.